Many companies are developing various therapies for the frontline, First R/R (transplant-eligible and transplant-ineligible), and subsequent R/R patients with DLBCL, such as Acerta Pharma BV/ Astrazeneca, Seattle Genetics/Takeda, ADC Therapeutics, Genmab, AbbVie, Bayer, and others.
DelveInsight’s “Diffuse Large B-cell Lymphoma (DLBCL) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diffuse Large B-cell Lymphoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Diffuse Large B-cell Lymphoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Diffuse Large B-cell Lymphoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Diffuse Large B-cell Lymphoma (DLBCL): An Overview
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that develops when B-lymphocytes become abnormal. It arises from the germinal center and post-germinal center B-cells. The etiology of DLBCL is complex and multifactorial. DLBCL can arise de-novo or from the transformation of indolent diseases like chronic lymphocytic lymphoma/small lymphocytic lymphoma (so-called Richter’s transformation), follicular lymphoma, and marginal zone lymphoma.
DLBCLs can be classified based on molecular heterogeneity (Cells of origin: germinal center B-cell (GCB); and activated B-cell [ABC or Non-GCB Subtype]); distinctive sites of presentation (primary CNS DLBCL, Primary cutaneous DLBCL, Intravascular large B-cell lymphoma) and stages (localized and advanced). Rare subtypes of DLBCL include primary mediastinal large B-cell lymphoma and primary effusion lymphoma (PEL).
Diffuse Large B-cell Lymphoma (DLBCL) Market Key Facts
-
According to the estimates, the highest market size of DLBCL is from the United States, in 2021 and is anticipated to grow at a CAGR of 10.4%.
-
Among EU4 countries, Germany has the maximum revenue share in 2021 while Spain has the lowest market share.
-
The market size of DLBCL in Japan is USD 448 million in 2021 which is expected to rise during the forecast period (2022-2032).
-
The total incident population of DLBCL in the 7MM comprised 73,598 cases in 2021 and is projected to increase during the forecast period.
-
The total incident population of DLBCL in the United States was 29,958 in 2021.
-
The United States contributed to the largest incident population of DLBCL, accounting for ~ 41% of the 7MM in 2021.
-
Among EU4 countries, Germany accounted for the highest number of DLBCL cases, whereas Spain accounted for the lowest cases in 2021.
-
In Japan, the total incident population of DLBCL was 11,409 in 2021 and is anticipated to rise during the forecast period.
Diffuse Large B-cell Lymphoma (DLBCL) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Diffuse Large B-cell Lymphoma pipeline therapies. It also thoroughly assesses the Diffuse Large B-cell Lymphoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Diffuse Large B-cell Lymphoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Diffuse Large B-cell Lymphoma (DLBCL) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Diffuse Large B-cell Lymphoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Diffuse Large B-cell Lymphoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Diffuse Large B-cell Lymphoma Epidemiology, Segmented as –
-
Total Incident Cases of Diffuse large B-cell Lymphoma [2019–2032]
-
Gender-specific Cases of Diffuse large B-cell Lymphoma [2019–2032]
-
Age-specific Cases of Diffuse large B-cell Lymphoma [2019–2032]
-
Type-specific Cases of Diffuse large B-cell Lymphoma [2019–2032]
-
Stage-specific Cases of Diffuse large B-cell Lymphoma [2019–2032]
Diffuse Large B-cell Lymphoma (DLBCL) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Diffuse Large B-cell Lymphoma market or expected to be launched during the study period. The analysis covers the Diffuse Large B-cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Diffuse Large B-cell Lymphoma drugs based on their sale and market share.
The report also covers the Diffuse Large B-cell Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Diffuse Large B-cell Lymphoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Diffuse Large B-cell Lymphoma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market
Diffuse Large B-cell Lymphoma (DLBCL) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Diffuse Large B-Cell Lymphoma. Currently, Genmab is leading the therapeutics market with its Diffuse Large B-Cell Lymphoma drug candidates in the most advanced stage of clinical development.
Diffuse Large B-cell Lymphoma (DLBCL) Companies Actively Working in the Therapeutics Market Include
-
AbbVie
-
Allogene Therapeutics
-
AstraZeneca
-
Autolus Therapeutics
-
Biogen
-
Calithera Biosciences
-
Debiopharm
-
Denovo Biopharma
-
Genmab
-
Gilead Sciences
-
IMV
-
Merck
-
Miltenyi Biomedicine
-
Novartis
-
Regeneron Pharmaceuticals
-
Roche
-
Seagen
-
Takeda
-
Xencor
-
Janssen
And Many More
Emerging and Marketed Diffuse Large B-cell Lymphoma Therapies Covered in the Report Include:
-
Glofitamab: Roche
-
Acalabrutinib: Acerta Pharma
-
AUTO 3: Autolus
-
Abexinostat: Xynomic Pharmaceuticals
-
Epcoritamab: AbbVie and Genmab
-
ALLO-501A: Allogene Therapeutics
-
LUNSUMIO (mosunetuzumab): Roche and Biogen
-
Zamtocabtagene autoleucel (MB-CART2019.1): Miltenyi Biomedicine
-
YESCARTA (axicabtagene ciloleucel): Kite Pharma (a subsidiary of Gilead Sciences)
-
KYMRIAH (tisagenlecleucel): Novartis
-
XPOVIO (selinexor): Karyopharm
-
POLIVY (polatuzumab vedotin-piiq): Roche/Chugai Pharmaceuticals
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Diffuse Large B-cell Lymphoma Competitive Intelligence Analysis
4. Diffuse Large B-cell Lymphoma Market Overview at a Glance
5. Diffuse Large B-cell Lymphoma Disease Background and Overview
6. Diffuse Large B-cell Lymphoma Patient Journey
7. Diffuse Large B-cell Lymphoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Diffuse Large B-cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Diffuse Large B-cell Lymphoma Unmet Needs
10. Key Endpoints of Diffuse Large B-cell Lymphoma Treatment
11. Diffuse Large B-cell Lymphoma Marketed Therapies
12. Diffuse Large B-cell Lymphoma Emerging Drugs and Latest Therapeutic Advances
13. Diffuse Large B-cell Lymphoma Seven Major Market Analysis
14. Attribute Analysis
15. Diffuse Large B-cell Lymphoma Market Outlook (In US, EU5, and Japan)
16. Diffuse Large B-cell Lymphoma Companies Active in the Market
17. Diffuse Large B-cell Lymphoma Access and Reimbursement Overview
18. KOL Views on the Diffuse Large B-cell Lymphoma Market
19. Diffuse Large B-cell Lymphoma Market Drivers
20. Diffuse Large B-cell Lymphoma Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Tonsillitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Tonsillitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Tonsillitis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/